Holen Sie sich die Stockscreener-App
0.3615
5.12%
-0.0195
Handel nachbörslich:
.38
0.0185
+5.12%
Schlusskurs vom Vortag:
$0.381
Offen:
$0.37
24-Stunden-Volumen:
91,821
Relative Volume:
0.34
Marktkapitalisierung:
$8.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-178.01M
KGV:
-0.0434
EPS:
-8.326
Netto-Cashflow:
$-7.87M
1W Leistung:
-9.63%
1M Leistung:
-44.12%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.3613
$0.40
1-Wochen-Bereich:
$0.36
$0.4111
52-Wochen-Spanne:
$0.36
$1.66
Lunai Bioworks Inc Stock (LNAI) Company Profile
Firmenname
Lunai Bioworks Inc
Sektor
Branche
Telefon
45 39179840
Adresse
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare LNAI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
0.3615 | 9.22M | 0 | -178.01M | -7.87M | -8.326 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lunai Bioworks Inc Aktie (LNAI) Neueste Nachrichten
Lunai Bioworks initiates employee furloughs and salary deferrals to preserve liquidity - Investing.com
Lunai Bioworks Furloughs Staff Amid Liquidity Constraints - TipRanks
Lunai Bioworks implements temporary furlough of employees in US and CanadaSEC filing - marketscreener.com
Lunai Bioworks implements temporary furloughs, execs defer salaries to preserve liquidity - TradingView
Financial Survey: Lunai Bioworks (NASDAQ:LNAI) versus Lite Strategy (NASDAQ:LITS) - Defense World
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - The Sheboygan Press
Lunai Bioworks Highlights Sentinel AI Safeguard After Anthropic CEO Warning on AI Chemical and Biological Threats - The Destin Log
LNAI Should I Buy - Intellectia AI
Lunai Bioworks Faces Nasdaq Delisting, Hearing Scheduled - TipRanks
Lunai Bioworks Received Notice of Delisting - TradingView
Head-To-Head Comparison: Lunai Bioworks (NASDAQ:LNAI) vs. NexImmune (OTCMKTS:NEXI) - Defense World
LNAI | Lunai Bioworks Inc. Common Institutional Ownership - Quiver Quantitative
LNAI | Lunai Bioworks Inc. Common Insider Trading - Quiver Quantitative
ENOB FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important September 26 Deadline in Securities Class ActionENOB - marketscreener.com
Lunai Bioworks Reports Q2 Loss - National Today
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping - Finviz
Lunai Bioworks Secures Foundational Patent to Strengthen AI Moat - Intellectia AI
Lunai Bioworks kicks off AI-driven oncology pilot to analyze phase 2 colorectal cancer trial - MSN
Lunai Bioworks: Second Quarter Financial Results Overview - Bitget
Lunai Bioworks: Fiscal Q2 Earnings Snapshot - marketscreener.com
Lunai Bioworks Inc. SEC 10-Q Report - TradingView
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC - Finviz
Lunai Bioworks Faces Nasdaq Delisting After Bid Price Breach - TipRanks
Lunai Bioworks Launches AI Oncology Pilot to Analyze Phase 2 Colorectal Cancer Trial Data - AIM Media House
Lunai Bioworks Updates Shareholders on February 2026 Operational Progress and Future Plans - geneonline.com
Lunai Bioworks, Inc. Issues Letter to Shareholders - The Malaysian Reserve
LNAI Partners on Phase 2 Cancer Trial to Enhance Patient Outcomes - GuruFocus
LNAI Strengthens AI Platform for Biotech Innovations and Partner - GuruFocus
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - Finviz
Lunai Bioworks (Nasdaq LNAI) launches AI oncology pilot - marketscreener.com
Lunai Bioworks (Nasdaq Lnai) Launches Ai Oncology Pilot - TradingView
Lunai Bioworks launches AI analysis of colorectal cancer trial data - Investing.com
Lunai Bioworks Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - marketscreener.com
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons - Finviz
Lunai Launches Sentinel AI Biosecurity Layer - Intellectia AI
AI safeguard Sentinel blocks novel chemical weapon designs at source - stocktitan.net
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery - The Malaysian Reserve
Lunai Bioworks launches alcohol use disorder drug discovery program By Investing.com - Investing.com Canada
Lunai Bioworks Expands NIH-Backed AI Platform Into Commercial Alcohol Use Disorder Drug Discovery - Nasdaq
LNAI Advances Drug Discovery Program for Alcohol Use Disorder - GuruFocus
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into - GuruFocus
Lunai Bioworks Launches Alcohol Use Disorder Program Following Key Milestones - Intellectia AI
Lunai Bioworks Inc. (LNAI) Presents at 44th Annual J.P. Morgan Healthcare ConferenceSlideshow - Seeking Alpha
Lunai Bioworks : JP Morgan Healthcare ConferenceMedTech Showcase Presentation - marketscreener.com
Lunai Bioworks (NASDAQ:LNAI) Raised to “Hold” at Wall Street Zen - Defense World
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance - GuruFocus
Lunai Bioworks: Year-End Partnering Momentum & Stock Setup - International Business Times
Lunai bioworks identifies three parkinsons disease subtypes By Investing.com - Investing.com South Africa
Lunai bioworks identifies three parkinsons disease subtypes - Investing.com
Lunai Bioworks identifies three Parkinson's disease subtypes - marketscreener.com
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market - Barchart.com
Finanzdaten der Lunai Bioworks Inc-Aktie (LNAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):